General
Preferred name
RIOCIGUAT
Synonyms
BAY 632521 ()
Riociguat (BAY 63-2521) ()
BAY-63-2521 ()
Adempas ()
BAY 63-2521 ()
Riociguat-13C-d3 ()
P&D ID
PD009166
CAS
625115-55-1
2749393-44-8
Tags
available
drug
Approved by
FDA
First approval
2013
Drug Status
approved
Drug indication
Pulmonary arterial hypertension
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation. Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. ; ; Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation.
TOXICITY EMBRYO-FETAL TOXICITY; Do not administer Riociguat to a pregnant female because it may cause fetal harm.; Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.; For all female patients, Riociguat is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy.
DESCRIPTION Riociguat is the first-in-class stimulator of soluble guanylate cyclase (sGC) class of drugs. (GtoPdb)
INDICATION Riociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class.; Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).
DESCRIPTION Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators. (BOC Sciences Bioactive Compounds)
Compound Sets
25
AdooQ Bioactive Compound Library
A11549
BOC Sciences Bioactive Compounds
riociguat-cas-625115-55-1-item-84-73664
Cayman Chemical Bioactives
9000554
25314
ChEMBL Approved Drugs
CHEMBL2107834
ChEMBL Drugs
CHEMBL2107834
Concise Guide to Pharmacology 2017/18
5257
Concise Guide to Pharmacology 2019/20
5257
Concise Guide to Pharmacology 2021/22
5257
Concise Guide to Pharmacology 2023/24
5257
Drug Repurposing Hub
DrugBank
DB08931
DrugBank Approved Drugs
DB08931
DrugCentral
4807
DrugCentral Approved Drugs
4807
DrugMAP
DMXBLMP
DrugMAP Approved Drugs
DMXBLMP
Guide to Pharmacology
5257
JUMP-Target 1 Compound Set
11304743
Mcule NIBR MoA Box Subset
MCULE-2362330080
MedChem Express Bioactive Compound Library
HY-14779
NCATS Inxight Approved Drugs
RU3FE2Y4XI
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
riociguat-bay-63-2521
TargetMol Bioactive Compound Library
T6968
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
422.16
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
4
cLogP
2.44
TPSA
138.07
Fraction CSP3
0.15
Chiral centers
0.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
Guanylate Cyclase
GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3
GUCY1B1
Member status
member
MOA
Guanylate Cyclase Activators
guanylate cyclase stimulant
Indication
hypertension
Source data